Gene expression analysis of enzalutamide resistant MDA PCa 2b prostate cancer cells
MDA PCa 2b is an androgen-responsive, AR-positive prostate cancer cell line.  Here, we report the generation of an Enzalutamide-resistant derivative, MDA PCa 2b-EnzaR. Gene expression of MDA PCa 2b-EnzaR compared to its parental counterpart were assessed by short-read RNA sequencing. Overall design: Differential gene expression analysis of RNA-seq data from enzalutamide sensitive (vehicle treated) and enzalutamide resistant MDA PCa 2b prostate cancer cells.